EC Number   |
Application |
Reference |
|---|
   3.1.3.16 | analysis |
assembly of a biosensor system involving protein phosphatase-2A and glycogen phosphorylase a activities, method optimization, overview |
707101 |
| 3.1.3.16 | diagnostics |
decreased PTPN12 protein level is associated with poor prognosis of several types of cancers |
750513 |
| 3.1.3.16 | diagnostics |
dephosphorylation of AKT by the PP2A phosphatase is known to be an important mechanism in determining the cellular levels of phosphorylated AKT |
752263 |
| 3.1.3.16 | drug development |
calcineurin is the principal target of the immunosuppressive drugs, cyclosporin A and FK506/Tacrolimus, the binding of which physically prevents the recruitment of macromolecular substrates to the active site |
751565 |
| 3.1.3.16 | medicine |
activating PP2A to dephosphorylate Bcl2 and/or increase Bcl2/p53 binding may represent an efficient and novel approach for treatment of hematologic malignancies |
691463 |
| 3.1.3.16 | medicine |
calcineurin is a target in treatment of myasthenia gravis, clinical factors of patients associated with responsiveness to calcineurin inhibitors, overview |
710027 |
| 3.1.3.16 | medicine |
MKP-1 inhibitors may have a use in cancer therapy |
692321 |
| 3.1.3.16 | medicine |
PP2A acts as a tumor suppressor |
691117 |
| 3.1.3.16 | medicine |
PP2A inhibition may offer a new therapeutic approach to the treatment of diseases caused by cerebral ischemia |
693780 |
| 3.1.3.16 | medicine |
PP4 regulates both apoptosis and proliferation in human cells and the level of PP4 has a strong influence on gene mutation rate, which is crucial to oncogenesis |
691081 |
